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Abstract: Alprazolam is an anti-anxiety drug shown to be effective in the treatment of depression. In this study, the effect of 
sympathetic receptor antagonists on alprazolam–induced antidepressant action was studied using a mouse model of forced 
swimming behavioral despair. The interaction of three sympathetic receptor antagonists with benzodiazepines, which may 
impact the clinical use of alprazolam, was also studied. Behavioral despair was examined in six groups of albino mice.  Drugs 
were administered intraperitoneally. The control group received only a single dose of 1% Tween 80. The second group 
received a single dose of alprazolam, and the third group received an antagonist followed by alprazolam. The fourth group 
was treated with imipramine, and the fifth group received an antagonist followed by imipramine. The sixth group was treated 
with a single dose of an antagonist alone (atenolol, a  1-selective adrenoceptor antagonist; propranolol, a non selective  -
adrenoceptor antagonist; and prazocin, an  1-adrenoceptor antagonist). Results confirmed the antidepressant action of 
alprazolam and imipramine. Prazocin treatment alone produced depression, but it significantly potentiated the antidepressant 
actions of imipramine and alprazolam. Atenolol alone produced an antidepressant effect and potentiated the antidepressant 
action of alprazolam. Propranolol treatment alone produced depression, and antagonized the effects of alprazolam and 
imipramine, even producing depression in combined treatments.In conclusion, our results reveal that alprazolam may produce 
antidepressant effects through the release of noradrenaline, which stimulates  2 receptors to produce an antidepressant 
action. Imipramine may act by activating  2 receptors by blocking or down-regulating  1 receptors. 
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Introduction 
Alprazolam has antidepressant activity and has been 
shown to be similar in efficacy to imipramine in the 
treatment of unipolar depression in humans. Thus, 
alprazolam may be particularly useful in patients with 
mixed anxiety / depression [1]. However, its general 
acceptance as an antidepressant awaits further study. 
Deficiency of serotonin, noradrenaline and dopamine is 
implicated as a causal factor in depression [2,3]. However, 
since the 1960s there has been a strong emphasis on the 
role of norepinephrine in both the pathogenesis of 
effective disorders and the mechanism of action of 
antidepressant medications [2,4-6]. Theories of depression 
also acknowledge that other factors may be involved; the 
antidepressants may act on other neurotransmitters, such 
as acetylcholine and gamma-aminobutyric acid (GABA). 
The monoamines, serotonin and norepinephrine, also 
influence and are influenced by other processes in the 
brain. The neurochemical basis of depression is now 
considered more complex and not the result of any one 
specific deficit [6]. For example, the function of the 
hypothalamic pituitary axis and the involvement of stress-
related hormones are increasingly believed to play a role 
in the development of depression [7]. 
 
It has been suggested that depression may result from 
down-regulation of the noradrenergic neuronal system, 
and antidepressants act to return the system to a state of 
equilibrium [8] by increasing neurotransmitter availability 
by a process that involves blocking reuptake in the 
presynaptic neuron. Consequently, the concentration of 
neurotransmitters in the synaptic cleft is increased [9]. 
 
Depression may also be due to a change in receptor 
function, not neurotransmitter concentration. As a result 
of preclinical investigation of antidepressant mechanisms 
of action, the monoamine hypothesis of depression was 
refined to include alterations in noradrenergic receptor 
function [10-12]. It has been suggested that the centrally 
active  1 and  2 adrenergic agonists produce 
antidepressant-like effects in several behavioral tests, 
suggesting that these receptors may be involved in the 
mediation of the effects of antidepressant drugs [13]. 
Down-regulation of  -receptors was proposed as the 
neuronal target for the effects of some antidepressants 
[14]. Duncan et al., [15] reported that imipramine, a 
common antidepressant drug, induces down-regulation of 
beta adrenergic receptors. Also, several studies revealed 
that  -adrenergic receptors may play an early role in the 
mechanism of depression and in the mechanism of action 
of antidepressants [16-18]. Thus,  -adrenoceptor 
dysfunction provides another hypothesis for pathogenesis 
of depression [19]. 
 
The forced swimming test (FST) is a behavioral 
paradigm predicative of antidepressant activity in rodents. 
The immobility exhibited by rodents when they are placed 
in an inescapable cylinder of water reflects the cessation 
of persistent escape-directed behavior [20]. Exposure to 
the forced swimming test is also known to produce 
changes in the release of dopamine, norepinephrine, and 
serotonin in a variety of brain regions, and these effects 
interact with antidepressant drug treatments [21,22]. 
 
Experimental work on the antidepressant effect of 
alprazolam on animal behavior is scanty. To further 
understand the significance of alprazolam in treating 
depression, it is essential to characterize the mechanisms 
underlying its action, as they may relate to the proposed 
mechanisms of depression. Norepinephrine is a candidate 
in both the pathogenesis of affective disorders and the 
mechanism of action of antidepressants [23,24]. 
Therefore, the present study was conducted to investigate 
the effect of sympathetic antagonists on the proposed 
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antidepressant action of alprazolam in mice subjected to 
the behavior despair method. 
 
Material and methods 
Albino mice weighing between 20 and 40 g were used. 
Groups of 7 mice each were kept in separate cages at 20–
25°C with 12 hours dark/light cycles. The drugs were 
suspended in 1% Tween 80 in water [25] because 
alprazolam is not freely soluble in saline; they were 
administered by the intraperitoneal route. Imipramine was 
used as the antidepressant [26], and the dose of 10 
mg/kg was selected on the basis of a pilot test. 
Alprazolam was given at 5 mg/kg, also after pilot testing. 
Sympathetic antagonists’ doses were based on previous 
studies [27, 30-33]. 
 
An experiment was conducted for each antagonist: 5 
mg/kg of prazocin [27-30], 5 mg/kg of atenolol [31,32], 
and 1 mg/kg of propranolol [27,30,31,33]. In each 
experiment, the mice were divided into six groups (n=7). 
Group 1 (control) received only a single dose of 5 ml/kg of 
1% Tween 80 (T80). Group 2 received a single dose of 5 
mg/kg alprazolam and group 3 received a single dose of 
the antagonist followed by the same dose of alprazolam (5 
mg/kg). Group 4 was treated with a single dose of 
imipramine (10 mg/kg) alone and group 5 received a 
single dose of the antagonist followed by the same dose 
of imipramine (10 mg/kg); Group 6 received a single dose 
of the antagonist alone. 
 
A modified behavioral model of immobility, known as 
behavioral despair [34-37], was used. In this model, mice 
are forced to swim in a restricted space from which there 
is no escape. Following an initial period of vigorous 
activity, the mice adopt a characteristic immobile posture 
and no longer attempt to escape. Mice were subjected to 
the test 60 minutes after administration of the drugs. They 
were forced to swim for six minutes in a vertical glass 
cylinder (height: 27 cm; diameter: 16.5 cm) containing 
fresh tap water at 27 °C and a depth of 15 cm [38]. The 
onset of immobility was recorded during the last four 
minutes of the six-minute testing period; mice were 
judged immobile when they floated in an upright position 
and made only small movements to keep their head above 
water. [37]. 
 
The data were analyzed by SPSS8 software. The 
Kolmogrov Simonov maximum deviation test for goodness 
of fit was used to determine if the data were normally 
distributed. Treatments were compared by one-way 
ANOVA if the parameters were parametric and by the 
Mann–Whitney two samples (non–matched) test if they 
were not. The differences were considered significant at 
p  0.05. 
 
Results
Administration of prazocin alone resulted in significantly 
faster onset of immobility as compared to the control 
group. By contrast, imipramine alone or alprazolam alone 
produced significant delay of the onset compared to the 
control group. Prazocin combined with alprazolam 
significantly delayed the onset of immobility compared to 
alprazolam treatment. Treatment with prazocin together 
with imipramine delayed the onset of immobility compared 
to imipramine treatment alone (Table 1). 
Table 1: Effect of prazocin on the onset of  immobility 
* Significantly different from the control T80-treated group at 
p 0.05.  a = significantly different from Alpr+Prz treated group at 
p 0.05; b = significantly different from Impr+Prz treated group 
at p 0.05.  
 
Administration of atenolol alone significantly delayed the 
onset of immobility compared to the control group. 
Administration of alprazolam alone caused a substantial 
delay (30-48%) in the onset of immobility compared to 
the control group (vehicle alone). However, the difference 
was statistically significant in only two of the three 
experiments. The effect of alprazolam was significantly 
potentiated when administered with atenolol. Imipramine 
administration produced significant delay in the onset of 
immobility compared to the control group. Administration 
of atenolol combined with imipramine did not significantly 
change the effect of imipramine (Table 2). 
 
Propranolol alone resulted in a significantly earlier onset 
of immobility compared to the control group. Alprazolam 
produced a significant delay in the onset of immobility 
compared to the control group. Imipramine significantly 
delayed the onset of immobility compared to the control 
group. The combination of propranolol and alprazolam 
produced significantly faster onset of immobility than 
observed in either the alprazolam or the control group. 
Propranolol significantly shortened the time to onset of 
immobility compared to the imipramine treated group or 
the control group (Table 3). 
 
Table 2: Effect of atenolol on the onset of immobility 
Treatment ( n = 7 )  Immobility onset 
(mean±SE, sec) 
T80 (1 ml/kg)  39.6 ± 0.69 
Alprazolam (5 mg/kg)  58.7 ± 10.34 a 
Alprazolam+ Atenolol  89.9 ± 0.77* 
Imipramine (10 mg/kg)  96.3 ± 3.09* 
Imipramine +Atenolol  98.4 ± 0.78* 
Atenolol (5 mg\kg)  88.7 ± 3.59*, b 
* Significantly different from the control T80-treated group at p  
0.05. a = significantly different from Alpr+Aten treated group at 
p 0.05; b = significantly different from Impr+Aten treated group 
at p 0.05.  
Discussion
The antidepressant effect of alprazolam was 
investigated using the forced swimming test as an acute 
stress model.  Although the forced swimming test does 
not induce in mice symptoms similar to human depression, 
it was used because it is simple and reliable across 
Immobility onset 
(mean± SE, sec) 
Treatment
( n = 7 ) 
38.2 ± 0.58  T80 (1 ml/kg) 
50.0± 0.71 *, a  Alprazolam (5 mg/kg) 
56.4 ± 0.68*  Alprazolam+ Prazocin 
60.0 ± 0.71*,  b  Imipramine (10 mg/kg) 
72.0 ± 1.82*  Imipramine + Prazocin 
1.4 ± 6.06*, a, b  Prazocin  (5 mg\kg) 
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laboratories. In addition, the majority of antidepressants 
have been shown to prolong the time to onset of the 
immobility, and their effectiveness correlates significantly 
with clinical potency [39] Alprazolam gave a uniform effect 
as an antidepressant in this animal model of depression. 
Mice treated with alprazolam showed a delay in the onset 
of immobility compared to the control group. The putative 
antidepressant effect of alprazolam may be mediated by a 
GABA-ergic mechanism that is independent of the 
benzodiazepine receptor. In a previous communication 
[40], it was reported that flumazenil (an antagonist at the 
benzodiazepine receptor), did not alter the antidepressant 
effect of alprazolam (or imipramine), whereas these 
effects were blocked by picrotoxin. Unlike diazepam, 
alprazolam may enhance the release of serotonin (5-HT) 
in the hippocampus, and this may at least partly explain 
its antidepressant activity [41]. Several observations 
indicate that alprazolam and standard antidepressants 
have some similar actions, such as the down-regulation of 
the beta-adrenergic receptor and their anti-anxiety effect 
[42]. 
 
Table 3: Effect of propranolol on the onset of immobility 
Immobility onset   
(mean±SE, sec) 
Treatment ( n = 7 )
53.6 ± 0.37  T80 (1 ml/kg) 
61.0 ± 1.23*, a  Alprazolam  (5 mg/kg) 
26.4 ± 0.57*  Alprazolam + Propranolol 
83.6 ± 0.99*, b  Imipramine (10 mg/kg) 
37.4 ± 1.10*  Imipramine + Propranolol 
36.6 ± 0.69*, a  Propranolol  (1 mg\kg) 
*Significantly different from the control T80-treated group at 
p  0.05. a = significantly different from Alpr+Prop treated group 
at p 0.05; b = significantly different from Impr+Prop treated 
group at p 0.05.  
 
The circulating level of corticotropin-releasing factor 
(CRF) is elevated in major depression and other 
psychiatric disorders [43,44]. In the forced swimming test, 
there is a dose-dependent increase of endogenous CRF, 
which may play a role in the behavioral response in this 
model [45]. CRF serves as a neurotransmitter in locus 
coeruleus, the largest aggregate of noradrenaline-
containing cells in the mammalian brain.  It is thought to 
be hypersecreted in depression and upon initiation of the 
stress response [46-48]. The inhibition of 5HT reuptake 
(by sertraline) may serve as a functional antagonist of CRF 
in depression [49]. Pharmacologically distinct 
antidepressants can interfere with CRF function in the 
locus coeruleus. This may be an important common 
mechanism for antidepressant activity [49]. Alprazolam 
may produce its antidepressant effect by decreasing the 
release of CRF in locus coeruleus, amygdala and several 
cortical regions [43]; it may also enhance the release of 
5HT in hippocampus [41], which would serve as a 
functional antagonist of CRF [49]. 
 
Imipramine, a typical antidepressant, produced a 
significant delay in the onset of immobility compared to 
the control group. Imipramine inhibits presynaptic 
reuptake of the biogenic amines, serotonin and 
noradrenaline to produce antidepressant action [50-52]. 
Imipramine may produce its antidepressant action through 
GABA-ergic mechanisms, causing the release of 
catecholamine [40,53-56]. Imipramine may also increase 
calcium release from intracellular stores [57]. 
 
Prazocin ( 1-adrenoceptor antagonist) alone produced 
depression, possibly by antagonizing endogenous 
noradrenaline. Prazocin produces CNS sympathetic 
inhibition indirectly through  2-adrenoceptor mechanisms. 
Reduction of  1 noradrenergic neurotransmission 
increases depressive behavior, coupled with the fact that 
this change can result from elevated corticosteroid 
secretion [58]. Prazocin significantly increased the 
antidepressant effects of imipramine. Prazocin may 
decrease the plasma level of interleukin-1 (stress marker) 
[59,60], which may lead to the potentiation of imipramine 
action. Imipramine may produce antidepressant effects 
through postsynaptic  2-agonist (clonidine), which will 
activate a sub-threshold dose of imipramine [37]. In an 
earlier study, small doses of clonidine potentiated the 
effects of antidepressants in the mouse in a similar forced 
swimming test [61]. Prazocin treatment with alprazolam 
has significant synergistic effects on alprazolam 
antidepressant action, which may occur by decreasing the 
level of interleukin–1 [59]. Also alprazolam, but not 
diazepam, activates brain  2-adrenoceptors. This may 
contribute to the effectiveness of alprazolam in the 
treatment of anxiety disorders [62]. Also, whereas 
alprazolam increases hippocampal 5-HT release, diazepam 
decreases it.  In the CA1 region of the hippocampus, the 
 2-adrenergic agonist clonidine increased 5-HT release 
[41]. The neurochemical profile of alprazolam was similar 
to that of the  2-adrenergic agonist, clonidine. Enhanced 
5-HT release in the hippocampus, exhibited by the atypical 
benzodiazepine, alprazolam but not by the typical 
benzodiazepine, diazepam, may be an underlying 
mechanism for the antidepressant activity of alprazolam 
[41]. Therefore, blocking  1 by prazocin may potentiate 
alprazolam action through the activation of  2 receptors. 
 
Atenolol is a selective  1 adrenoceptor antagonist, and 
by itself it produced significant antidepressant action. This 
effect may be through blocking  1 receptors [63]. At least 
in some instances, the antidepressant effect of atenolol 
may be mediated by the down-regulation of  1-
adrenoceptor [64,65]. In general, receptor down-
regulation is a long-term effect of chronic drug 
administration and does not occur acutely following the 
administration of a single dose. Also, atenolol is a 
hydrophilic molecule that does not easily penetrate the 
blood-brain barrier [63]. Therefore, it is safe to rule out 
 1-adrenoceptor down-regulation as the mechanism for 
the atenolol effect observed in our study.  
 
Several possibilities may explain the antidepressant 
effect of atenolol. The dose used in this study was 
sufficient to partially penetrate the CNS and produce the 
observed effect. Atenolol may act peripherally to initiate 
an unknown mechanism that affects the noradrenergic 
system centrally. It is also possible that the atenolol 
observations may constitute a false positive result of a  -
blocker. Blocking a steady-state agonist response to 
measure the potency of an antagonist might in some 
cases yield erroneous results and the response should be 
interpreted cautiously [66]. 
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Contrary to our data, several human studies showed 
depressive symptoms after atenolol. Most of the authors 
suggested that atenolol lowers melatonin release via 
specific inhibition of  1-adrenoreceptors. The decrease in 
melatonin may contribute to the disturbance in sleep and 
mood associated with atenolol use [19,67-70]. In our 
study atenolol did not change the effect of imipramine 
significantly, possibly because the maximal capacity of 
imipramine to down regulate the  -receptor was reached. 
Therefore, atenolol acting by the same mechanism did not 
change imipramine antidepressant effects significantly. 
Atenolol produced a significant synergistic effect on 
alprazolam antidepressant action. This effect can be 
explained by the pronounced  2 receptor activity due to 
the blocking of  1 receptor. This explanation may be 
accepted if the dose used in this study was enough for 
atenolol to partially penetrate the CNS, or atenolol could 
be acting through a peripheral mechanism to induce this 
effect. Alprazolam induces release of noradrenaline 
through a GABA-ergic mechanism [40,52-55], which 
stimulates the sensitive  2-receptor, and as a result 
atenolol significantly potentiates the antidepressant action 
of alprazolam. Alprazolam did not change the effect of 
atenolol; this is observed by comparing the group treated 
with atenolol alone to the combined treatment with 
atenolol and alprazolam. This may be due to the maximum 
effect produced by both drugs on  1 (inhibition) and  2 
(stimulation).  
 
Propranolol alone showed a significant depression. This 
may be due to blocking  2 and  1 receptors. Blocking  1 - 
receptors produces antidepressant action as observed by 
the atenolol effect, while blocking both  1 and  2 
receptors produced depression. This indicates that  2 
stimulation produces antidepressant effect. Reduced 
central  -receptor activation may contribute to depressive 
symptoms associated with  -adrenergic blocking drugs 
[71]. In the forced swimming test, it was found that 
isoprenaline increases the duration of immobility, while 
salbutamol decreases it [72]. The central  1and  2 
receptors may be acting in opposite direction to modify 
the duration of immobility which means that activation of 
 1 leads to enhanced behavioral despair while  2 
activation reverses this effect [72]. In animals, the 
psychopharmacological profile of  2 stimulant 
(salbutamol) is, to a certain extent, very similar to tricyclic 
antidepressant drugs such as imipramine [73,74]. In 
endogenous depressive patients, the antidepressant effect 
of salbutamol is both clear and rapid [73,75]. It was 
speculated that the antidepressant effect of imipramine is 
related to the stimulation of central  2 adrenergic 
receptors [73]. Both salbutamol and imipramine prevent 
or reverse reserpine induced hypothermia while these 
effects were antagonized by propranolol, suggesting that 
the stimulation of  -adrenergic receptors could be a 
common mechanism underlying their effects [76]. 
Stimulation of the central  2 adrenergic receptor, 
particularly those located in the hippocampus, produces 
antidepressant-like effects on behavior [77]. Also,  2 
agonist (salbutamol) facilitates 5HT transmission in the rat 
brain probably via stimulation of central   receptors [78]. 
The reduction in Ca2+i that is caused by inhibiting Ca2+ 
influx through voltage-gated channels and by enhancing 
Ca2+ efflux may contribute in part to the antidepressant-
like activity shown by salbutamol, as verapamil and 
nifedipine possessed antidepressant-like properties 
[79,80].  
 
Imipramine may cause down regulation or blockade of 
 1 receptors, thus the balance between  1 and  2 
receptors is disturbed leading to the predominance of  2–
receptor activity which produces an antidepressant effect. 
Blocking  1 or stimulation of  2 receptors may mediate 
the mechanism of imipramine antidepressant action. 
Administration of propranolol with imipramine produced 
significant antagonism of imipramine antidepressant 
effect, and even produced significant depression. This 
observation may be explained by the blockade of  2–
adrenoreceptors. 
 
Propranolol, a non-selective  -blocker, combined with 
alprazolam abolished alprazolam antidepressant effects 
and even produced significant depression. Alprazolam 
induces the release of mono-amine transmitters through 
GABA-ergic system [53-56]. Stimulation of the  2–
adrenoreceptors by the released noradrenaline leads to 
antidepressant action. Our observation of the depressant 
effect of propranolol agrees with previous studies which 
associate   blockers with induction of symptoms of 
depression as mentioned above. 
 
In conclusion, this study demonstrates that alprazolam 
has a significant antidepressant effect in the rodent forced 
swimming behavioral model. Our data also indicate that 
this effect may be mediated by the release of 
noradrenaline, which stimulates  2-adrenoeceptors. 
Imipramine may produce its antidepressant action through 
the activation of  2 receptors by down regulating or 
blocking the  1-receptor. 
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